Retrospective analysis reveals salvage therapies improve progression-free survival in large B-cell lymphoma post CAR T-cell treatment, suggesting new standards are needed.
Key Points
Salvage therapies improved progression-free survival in patients with large B-cell lymphoma after CAR T-cell therapy relapse, with notable response rates.
Overall survival after relapse was median 6.5 months, highlighting the need for better treatment strategies in this high-risk group.
Retrospective analysis using the French DESCAR-T registry assessed various salvage therapies and their effectiveness post-relapse.
Clinical outcomes varied significantly with treatment type, emphasizing the urgency for prospective trials in large B-cell lymphoma patients.